Pharmaceutical Benefit Manager, Express Scripts $ESRX is rummored to be the target of a $67 billion deal from Health Insurer Cigna $CI. This would be a 31% premium to the 3/7 closing price of $73.42. (Reuters) ESRX share price opened with a gap up to $85.07 before sliding down sharply. Some quick profits were made here. But what about the overall market? I think if price can hold above $80 this week, ESRX should remain bullish with upside towards $94. I had this bullish outlook for ESRX before the acquisition talks based on price action, but it depended it holding above $66. ESRX Daily Chart (click to enlarge) Bulls Stalling:- The $80 mark is indeed a key support/resistance pivot. - Will price be able to pivot higher from $80?- If so, the prevailing uptrend is still alive.- A look at the weekly chart shows a secular bull market for ESRX.- Indeed the only reason we might be concerned is the acquisition, which is not necessarily a good thing outside of the short-term price pump. - Still, it looks like price will be able to push towards the 2015 high just under $95, with possible extension towards the $100 mark, which is the upper limit to my bullish outlook for now. ESRX Weekly Chart (click to enlarge)